The global rheumatoid arthritis drugs market is expected to grow from USD 23.55 billion in 2023 to USD 53.25 billion by 2033, at a CAGR of 8.50% during the forecast period 2024-2033. Global rheumatoid arthritis drugs market is witnessing a considerable growth owingto the rise in geriatric population all across the globe. Rising awareness about rheumatoid arthritis and its treatment will drive market growth. Ongoing research and development for Rheumatoid Arthritis Drugs will help the healthcare industry develop effective medicines.

Market Overview:

Rheumatoid arthritis (RA) is a prolonged systemic auto-immune disease that largely affects the lining of the synovial joints in the body and is associated with premature death, progressive disability, and to some extent socioeconomic burdens.Rheumatoid Arthritis is usuallycategorizedtenacious soreness and inflammation that mainly affects the peripheral joints.Rheumatoid arthritis is characterized as a symmetrical/bilateral pattern of disease progression. This is because in this disease joints of the knees and legs are first affected. The joint’s lining becomes inflamed causing tissue damageeventually leading tounsteadiness, chronic pain, and deformity. This disease can also affect extra-articular regions of the body including themouth, eyes, lungs, and heart. The symptoms associated with rheumatoid arthritis are:

• Pain associated with the stiffness in more than one joint
• Weight loss
• Fever
• Fatigue, or tiredness
• Weakness

According to the data published by the World Health Organization, about 1% of the population across the globe is diagnosed by rheumatoid arthritis.As per study, the female population is much more prone to this disease as compared to the male population. As permanent cure for rheumatoid arthritis is not there (available), sometimes physiotherapy treatments procedures are done to the patients. The focus of these treatment procedures are to prevent bone deformity, minimize pain, reduce inflammation, and optimize &improve the patient’s overall function. This can be achieved by the utilization of assistive devices, exercise coupled with pain medication medicines, NSAIDs and steroids which areoften used to aid with the symptoms that a patient is facing. For instance, the disease-modifying anti-rheumatic drugs (DMARDs) are utilized in order to minimize the pain associated with the rheumatoid arthritis. Scientistshave proven that these drugs can be used for rheumatoid arthritis as primary treatment and have been found to improve the symptoms, decrease joint damage, and aids in recovering the overall functional abilities of the patient.

Get an overview of this study by requesting a free sample

Market Dynamics:

Drivers:

• Rising Geriatric Population

According to World health organization, the population aged 60 years and older is expected to total 2 billion by 2050, up from 900 million in 2015. Around 125 million people are aged 80 years or older in the present scenario. A shift in the distribution of country’s population towards older population (population ageing) started in developed and high income countries, it is now the developing countries that are going through the greatest change. The pace of population ageing across the globe is also rising vividly. The data also predicts about 80% of all older people will live in low and middle-income countries. Older age is also characterized by the emergence of several complex health states be likely to occur only later stages in life and these do not fall into distinct disease or their categories. Rheumatoid arthritis is most common in the old-age population. Thus, this primary factor is going to drive the market growth and development in the present scenario.

• Increasing Incidences of Rheumatoid Arthritis

In the present scenario, there has been an upsurge in the rising incidences of rheumatoid arthritis. According to the research study conducted by Global Burden of Disease and Injuries, between 1 and 2 million of the population in North America suffer from of the rheumatoid arthritis. The study revealed the factors such as continuous cigarette smoking, vitamin D deficiency and lower dose synthetic estrogens in oral contraceptives are the main causes of rheumatoid arthritis to occur. This particular disease is often associated with increased morbidity rate, work-related disability, and shortened survival. Up to one-half of all rheumatoid arthritis patients become unable to work within 10 to 20 years of time period. This disease have a 60% to 70% higher mortality risk than those in the general population. Thus, higher instances of the rheumatoid arthritis in developed regions such as North America going to increase the demand of the pharmaceutical drugs in the market.

Restraints:

• High Cost Associated with the Manufacturing of Biosimilar Drugs

The interest of the biosimilar drugs continues to rise and pharmaceutical& drug manufacturers are making huge capital expenditure for new drug formulations in order to survive in a competitive environment. Biosimilar drugs are gaining a lot of attention due to the apparent cost-savings that consumers hope to gain coupled with opportunities for alternative pharmaceutical drug producers to enter both emerging and established markets. However, the whole manufacturing process of the biosimilar drugs and their products requires careful and strict manufacturing practices owing to the stringent rules and regulations formulated by U.S. Food and Drug Administration (FDA) regarding safety, requires a high cost and expenditure. Thus the price of the end-product also rises. Thus, this factor is going to restrain the market growth and development for the rheumatoid arthritis drugs market.

Opportunities:

• The Increasing Acceptance of Large Molecules Biologics by Rheumatologists

The increasing acceptance of the large molecule biologics by the rheumatologists is going to provide potential opportunities for the market to grow and flourish. Traditionally, autoimmune diseases such as rheumatic arthritis are tackled and managed by using biologics. Biologics are far more complex at the molecular level in comparison traditional chemically manufactured pharmaceuticals and drugs. They are much larger molecules than other drug classes of pharmaceuticals with an average molecular mass 100 times greater in comparison to aspirin. Their size and biologic properties preclude oral administration.

Challenges:

• Availability of Alternative Non-Drug Pain Management Therapies

The availability of non-drug pain management therapies and natural remedies for rheumatoid arthritis is going to hamper the market development and growth in the recent years. Natural remedies such as acupuncture, Tai-chi, and other exercises may is gaining popularity among the population. Studies have shown that acupuncture is rapidly becoming a mainstream treatment for pain. Acupuncture works for pain caused by many conditions, including fibromyalgia, arthritis, back injuries, sprain and sports related injuries. Tai-chi is an ancient martial art technique which helps dealing with rheumatoid arthritis. Tai-chi involves with slow and gentle movements along with deep breathing. Additionally, pain relieving gels, topical creams, and lotions if rubbed directly onto the skin helps in pain relieving.

Segmentation analysis:

The global rheumatoid arthritis drugs market has been segmented based on type, mode of distribution, mode of administration and regions.

• The type segment is divided intopharmaceuticals and biopharmaceuticals. The biopharmaceutical segments led the rheumatoid arthritis drugs market with a market share of around 58.4% in 2023. The segment growth is mainly attributed because of the rising acceptance of the biologics and biosimilar drugs by the rheumatologists.They adopt the approach of applying biosimiar medicines and biologics because these drugs helps in tackling the auto-immune diseases like rheumatoid arthritis very efficiently. 
• The mode of distribution segment includesOTC (Over the counter) and prescription. The prescription segment is estimated to grow at the highest CAGR of 4.6% over the forecast period. The segment growth is attributed owing to the increasing consultation activities of the rheumatoid arthritis. Extended drug usage catering to rheumatoid arthritisoften leads to drug resistance. So the patients are advised to go for the consultations.
• By mode of administration, the market is segmented into oral, subcutaneous and intravenous. The oral segment is expected to hold the largest market share of the global rheumatoid arthritis market in 2023. The segment growth is mainly attributed because of the ongoing prevalence of the oral based pharmaceutical drugs for the rheumatoid arthritis in and across the globe.

Regional segmentation analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa.North America region emerged as the largest market for the rheumatoid arthritis drugs market with around 56.1% share of the market revenue in 2023.

Check the geographical analysis of this market by requesting a free sample

• The regional growth is attributed wing to the increase in geriatric population in and across the region. Also, the rising incidents on the rheumatoid arthritis in U.S. is going to spur the market growth and development in the North America region.
• The market in the Asia Pacific is expected to grow at the highest CAGR over the forecast period owing to the rising healthcare expenditure amongst the population in the region. Also, the drug manufacturing companies are gradually shifting their production facilities in the developing and emerging nations because the cost associated with manufacturing of pharmaceuticals drugs is comparatively low.

Competitive Analysis:

The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances and partnerships to improve their market position in the global rheumatoid arthritis drugs industry.

In August 2019, AbbVie received the FDA Approval for RINVOQ (upadacitinib). The product is an oral JAK Inhibitor utilized for the treatment of moderate to severe rheumatoid arthritis.

In February 2019, Pfizer Inc. has started their serious developments regarding product differentiation by observing their rheumatoid arthritis patients.

List of Key Market Players:

• BoehringerIngelheim GmbH
• Regeneron Pharmaceuticals, Inc.
• Johnson & Johnson
• Amgen Inc.
• Eli Lilly
• Bristol-Meyers Squibb Company
• UCB S.A.
• Pfizer, Inc.
• AbbVie
• F. Hoffmann-La Roche AG
• Novartis International AG

Key Target Audience

• Pharmaceutical Drug Manufacturer
• Rheumatoid Arthritis Treatment Centers
• Research and Development (R&D) Companies
• Government Research Laboratories
• Government Authorities And R&D Institutions
• Academic & Medical Research Institutions

Report Description:

• Global Rheumatoid Arthritis Drugs Market, Industry Analysis, Trends, Analysis and Forecast, 2024 to 2033 is a forthcoming/imminent research report which is to be published by The Brainy Insights.
• 2023 is considered as the base year of the report. 2020 to 2022 are considered as the historic years and 2024 to 2033 are the forecast years. The global rheumatoid arthritis drugs market is based on revenue (USD Billion). The report incorporates the market study on the basis of revenue. The study covers the market share revenue/market share for each of the segments, regions and countries catering to global rheumatoid arthritis drugs market. The regions analyzed for the market are Europe, Asia Pacific, North America, South America and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
• The report encompasses with the relative data & information, which have been validated by the leading industry professionals and experts all across the globe. The research report also delivers an outline of the attractiveness of rheumatoid arthritis drugs market on the basis of type, mode of administration, mode of distribution and regions which are deduced and formulated on the basis of their growth rate (CAGR), market size, and attractiveness by analyzing the present and future prospects to fathom market growth and development in future.
• The report illustrates the detailed (both quantitative and qualitative) analysis of historical data, revenues, key developments, along with the crucial strategies adopted by key organizations catering to global rheumatoid arthritis drugs market. This offers vital and in depth insights in order to depict the overall market scenario.
• The report offers the detailed study for the company profiles of key organizations operating in the global rheumatoid arthritis drugs market and a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development & innovations, recent developments, joint venture, partnerships, mergers & acquisitions, strategic alliances, SWOT analysis, and key financial information. This helps in evaluating the overall competition present in the market scenario.
• The report provides an elaborative assessment of the porter’s five forces analysis coupled with SWOT analysis so as to provide business related data and information’s. Porter’s five forces model is analyzed to understand the overall competitive scenario that is prevailing in the market. Additionally, the SWOT analysis identifies both the positive and negative attributes of the market development which influences the company growth and development in order to sustain and survive in the long run.
• Along with that, the report also focuses on the market related driving factors, growth limitations (restraints), potential industry opportunities, significant trends and development which acts as a key potential for the investors.
• Potential growth prospects along with the penetration rate analysis of the products (market related i.e., global rheumatoid arthritis drugs market) is covered in order to comprehend the adoption rate and evaluate the market size.